Search our Database of Scientific Publications and Authors

I’m looking for a

    1133 results match your criteria Extracorporeal Photopheresis

    1 OF 23

    Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems.
    Transfusion 2018 Feb 16. Epub 2018 Feb 16.
    Bone Marrow Transplant Program, University of Kansas Medical Center, Kansas City, Kansas.
    Background: Extracorporeal photopheresis (ECP) has been approved for the treatment of advanced cutaneous T-cell lymphoma since 1988. While the precise mechanisms resulting in clinical effects are not fully understood, the photoactivation of mononuclear cells (MNCs) using ultraviolet A (UVA) light and methoxsalen is believed to be the predominant initiating process. The effects of MNC passage through the instrument without photoactivation are unknown. Read More

    Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter?
    Transfusion 2018 Feb 15. Epub 2018 Feb 15.
    Division of Hematology, Medical University of Graz, Graz, Austria.
    Background: Extracorporeal photopheresis (ECP) has demonstrated efficacy as second-line treatment for steroid-refractory (SR) acute graft-versus-host disease (aGVHD). The aim of our study was to analyze whether the amount of ECP-treated cells in patients with SR, aGVHD has an impact on response at 1 month.

    Study Design And Methods: Data on white blood cells, lymphocytes, monocytes, mononuclear cells, and neutrophils, including absolute counts and counts per kilogram of body weight in ECP products from patients with aGVHD, were collected. Read More

    An ex vivo comparison of vascular access devices used in extracorporeal photopheresis.
    Transfusion 2018 Feb;58 Suppl 1:609-613
    Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri.
    Background: Central venous access devices are commonly used in extracorporeal photopheresis, but their performance has not been systematically evaluated. The primary objective of this study was to compare pressures at various flow rates for central venous access devices in an ex vivo simulation of photopheresis.

    Study Design And Methods: Diluted, heparinized red blood cells were circulated through central access devices in series with a photopheresis system, and pressures at several flow rates were recorded. Read More

    Vascular access considerations for extracorporeal photopheresis.
    Transfusion 2018 Feb;58 Suppl 1:590-597
    Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, Arizona.
    Extracorporeal photopheresis is an immunomodulatory therapy indicated for patients with cutaneous T-cell lymphoma, graft-versus-host disease, and heart or lung allograft rejection. Whole blood from the patient is drawn into the photopheresis instrument where it is separated into its components. Plasma, red blood cells, and the treated buffy coat are subsequently returned to the patient. Read More

    Thymopoiesis following HSCT; a retrospective review comparing interventions for aGVHD in a pediatric cohort.
    Clin Immunol 2018 Jan 27. Epub 2018 Jan 27.
    Institute of Cellular Medicine, Newcastle University, United Kingdom; Great North Childrens' Hospital, Newcastle-upon-Tyne, United Kingdom.
    Acute graft-versus-host disease (aGVHD) complicates allogeneic hematopoietic stem cell transplantation (HSCT), and is treated with topical and/or systemic corticosteroids. Systemic corticosteroids and aGVHD damage thymic tissue. We compared thymopoietic effect of topical steroid therapy, corticosteroids and extracorporeal photopheresis (ECP) in 102 pediatric allogeneic HSCT patients. Read More

    Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation.
    Pediatr Transplant 2018 Jan 29. Epub 2018 Jan 29.
    Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
    ECP is an established "second-line" treatment for CLAD/BOS. Recently, ECP was used for the first time in an adolescent CF patient as a "second-line" treatment therapy in life-threatening primary graft dysfunction following lung transplantation who deteriorated despite extensive treatment including ECMO and ATG. Within 10 days after initiation of ECP twice weekly, allograft function and clinical status improved significantly and the patient was weaned from mechanical ventilation support. Read More

    [Cutaneous graft-versus-host disease].
    Hautarzt 2018 Feb;69(2):109-115
    Universitätsklinik für Dermatologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
    Background: Graft-versus-host disease (GvHD) is a complex multiorgan disease, which can occur as a complication following allogeneic stem cell transplantation. Involvement of the skin represents the most common appearance of GvHD. The role of the dermatologist is critical for diagnosis and initiation of treatment. Read More

    Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease.
    Hematology Am Soc Hematol Educ Program 2017 Dec;2017(1):639-644
    Northwestern University Feinberg School of Medicine, Chicago, IL.
    Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for many disease states. Despite significant improvements in strategies used to prevent and treat acute and chronic graft-versus-host disease (a/cGVHD), they continue to negatively affect outcomes of HSCT significantly. Standard, first-line treatment consists of corticosteroids; beyond this, there is little consistency in therapeutic regimens. Read More

    Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.
    Exp Hematol Oncol 2017 2;6:32. Epub 2017 Dec 2.
    Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Manuel Siurot 41013, Seville, Spain.
    Background: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. Read More

    Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization.
    J Clin Apher 2017 Nov 28. Epub 2017 Nov 28.
    Division of Hematology and Oncology and the, The Blood and Marrow Transplant Program, Lebanon, New Hampshire, 03756.
    Extracorporeal photopheresis (ECP) is an established therapy for the treatment of graft-versus-host-disease (GVHD) following an allogeneic stem cell transplant. We performed a prospective analysis of patients receiving ECP treatment for GVHD to identify a clinical pathway and resource utilization of this process. The cohort included consecutive allogeneic stem cell recipients with GVHD. Read More

    An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
    J Dermatolog Treat 2017 Dec 18:1-9. Epub 2017 Dec 18.
    b Strategic Therapeutics, LLC , Oro Valley , AZ , USA.
    Purpose: To conduct an exploratory cost-effectiveness analysis of systemic treatment options for more advanced cutaneous T-cell lymphoma (CTCL).

    Methods: A cost-effectiveness model compared systemic bexarotene, denileukin diftitox, interferon-α, methotrexate, pralatrexate, romidepsin, vorinostat, and extracorporeal photopheresis (ECP) treatment of CTCL. Treatment effectiveness data were extracted from published studies and/or US product labeling. Read More

    Epidemiology of therapeutic apheresis with a multidisciplinary approach at a high volume pediatric center.
    J Clin Apher 2017 Nov 15. Epub 2017 Nov 15.
    Department of Pathology, Emory University, Atlanta, Georgia.
    Introduction: Therapeutic apheresis (TA) is used inconsistently in pediatric populations. We seek to define our multidisciplinary institutional practice.

    Methods: We conducted a retrospective chart review of patients receiving TA from January 1, 2012 through October 31, 2015. Read More

    "Best practice" for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa' Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers.
    Transfusion 2018 Jan 13;58(1):217-222. Epub 2017 Nov 13.
    Department of Internal Medicine, Marche University, Ancona, Italy.
    Background: A recent "best practice" promoted and published by Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societa' Italiana di Emaferesi and Manipolazione Cellulare (SIDEM) on the use of extracorporeal photopheresis (ECP) in acute and chronic graft-versus-host disease (GVHD) has been tested for the degree of agreement and application among Italian transplant centers.

    Study Design And Methods: Twenty-four Italian centers coordinating a pair number of transplant programs completed the Web-based survey within the fixed deadline, representing approximately 52% of those centers that have a GITMO-accredited allogeneic transplant program that routinely uses ECP in GVHD.

    Results: The level of full agreement was more than 85% for most of the answers given by the best practice (14 of 16) to the various issues. Read More

    Ultraviolet Irradiation of Blood: "The Cure That Time Forgot"?
    Adv Exp Med Biol 2017 ;996:295-309
    Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, USA.
    Ultraviolet blood irradiation (UBI) was extensively used in the 1940s and 1950s to treat many diseases including septicemia, pneumonia, tuberculosis, arthritis, asthma and even poliomyelitis. The early studies were carried out by several physicians in USA and published in the American Journal of Surgery. However with the development of antibiotics, UBI use declined and it has now been called "the cure that time forgot". Read More

    Cutaneous Chronic Graft Versus Host Disease Following Allogeneic Haematopoietic Stem Cell Transplantation in Children: A Retrospective Study.
    Acta Derm Venereol 2018 Feb;98(2):206-211
    Department of Dermatology, Hadassah-Hebrew University Medical Center, Kiryat Hadassah, POB 12000, Jerusalem, 9112001, Israel.
    Chronic graft versus host disease (cGVHD) is a complication of allogeneic haematopoietic stem cell transplantation (HSCT). The aim of this study was to clinically characterize childhood cutaneous cGVHD. A retrospective study of children treated with HSCT at 2 tertiary medical centres in Israel between 2011 and 2014 was performed. Read More

    A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease.
    Biomedicines 2017 10 11;5(4). Epub 2017 Oct 11.
    Department of Blood & Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
    Although significant advances have been made in the biologic understanding of graft-versus-host disease (GVHD) and its treatment options, GVHD remains the single most challenging obstacle to the success of allogeneic hematopoietic cell transplantation (HCT) due to high risk of disabling morbidity and mortality. Extracorporeal photopheresis (ECP) has promising effects in controlling steroid-refractory GVHD, both acute and chronic, and it has been studied extensively. Its putative immunomodulatory mechanisms, while not immunosuppressive, position ECP as an attractive treatment strategy for GVHD patients who are already receiving global immunosuppression. Read More

    Extracorporeal photopheresis: Review of technical aspects.
    Asian J Transfus Sci 2017 Jul-Dec;11(2):81-86
    Department of Transfusion Medicine and Hematology, BLK Super Speciality Hospital, New Delhi, India.
    Extracorporeal photochemotherapy (ECP) is considered as an immune modulating therapy majorly targeting the T cells of the Immune system. ECP induces an anti-inflammatory condition with tolerogenic responses without inducing a global immunosuppression state which is a typical feature of other therapeutic options such as steroids. Clinical indication of ECP has grown over time since its initial applications. Read More

    Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
    Ann Oncol 2017 Oct;28(10):2517-2525
    Department of Dermatology, Stanford University Medical Centre, USA.
    Background: Advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) patients are weighted by an unfavorable prognosis and share an unmet clinical need of effective treatments. International guidelines are available detailing treatment options for the different stages but without recommending treatments in any particular order due to lack of comparative trials. The aims of this second CLIC study were to retrospectively analyze the pattern of care worldwide for advanced-stage MF/SS patients, the distribution of treatments according to geographical areas (USA versus non-USA), and whether the heterogeneity of approaches has potential impact on survival. Read More

    The Barcelona Hospital Clínic therapeutic apheresis database.
    J Clin Apher 2017 Sep 22. Epub 2017 Sep 22.
    Apheresis Unit, Department of Hemotherapy and Hemostasis, ICMHO, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain.
    Introduction: A therapeutic apheresis (TA) database helps to increase knowledge about indications and type of apheresis procedures that are performed in clinical practice. The objective of the present report was to describe the type and number of TA procedures that were performed at our institution in a 10-year period, from 2007 to 2016.

    Material And Methods: The TA electronic database was created by transferring patient data from electronic medical records and consultation forms into a Microsoft Access database developed exclusively for this purpose. Read More

    Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease.
    Lung 2017 Dec 11;195(6):781-788. Epub 2017 Sep 11.
    Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA.
    Purpose: Rituximab is an anti-CD20 monoclonal antibody that is used to suppress B-cell function in graft-versus-host-disease (GVHD). We sought to determine the effects of rituximab treatment on lung function in those patients with bronchiolitis obliterans syndrome (BOS) as a manifestation of GVHD.

    Methods: Thirteen patients were treated with rituximab with a diagnosis of BOS and a significant reduction in the forced expiratory volume in 1 s (FEV1) after hematopoietic stem cell transplantation (HSCT). Read More

    Mononuclear cell collection for extracorporeal photopheresis: Concentrate characteristics for off-line UV-A irradiation procedure.
    J Clin Apher 2017 Aug 22. Epub 2017 Aug 22.
    Transfusion Medicine Department, Catholic University of Rome, Rome, Italy.
    Background And Objective: Extracorporeal photopheresis (ECP) is the most represented cell therapy for treatment of cutaneous T-cell lymphoma, graft-versus host disease and organ rejection. We analyzed our experience in ECP using 2 cell separators (Cobe Spectra and Spectra Optia) focusing on leukapheretic product characteristics, UV-A irradiation procedure and entire ECP process.

    Materials And Methods: We collected data of patients undergoing ECP between January 2012 and February 2015 in order to evaluate collection procedures performed using Cobe Spectra and Spectra Optia, mononuclear cell product, UV-A photoirradiation procedure by Pit System. Read More

    How to perform extracorporeal photopheresis via port catheter.
    Transfusion 2017 Nov 7;57(11):2567-2570. Epub 2017 Aug 7.
    Department of Dermatology, Venereology and Allergology, University of Leipzig, Leipzig, Germany.
    Background: Extracorporeal photopheresis (ECP) is commonly performed via peripheral venous access catheter. If this is not possible, a tunneled central venous catheter may be considered. However, this access mode may be associated with high complication rates. Read More

    Analysis of long term CD4+CD25highCD127- T-reg cells kinetics in peripheral blood of lung transplant recipients.
    BMC Pulm Med 2017 Jul 18;17(1):102. Epub 2017 Jul 18.
    Department of Internal Medicine, University of Pavia, Pavia, Italy.
    Background: The role of CD4CD25CD127T-reg cells in solid-organ Transplant (Tx) acceptance has been extensively studied. In previous studies on kidney and liver recipients, peripheral T-reg cell counts were associated to graft survival, while in lung Tx, there is limited evidence for similar findings. This study aims to analyze long term peripheral kinetics of T-reg-cells in a cohort of lung recipients and tests its association to several clinical variables. Read More

    Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis.
    Case Rep Dermatol Med 2017 12;2017:3240287. Epub 2017 Jun 12.
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA.
    Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is a rare complication of exposure to gadolinium-based contrast agents in patients who have significantly decreased renal function. Manifestations include fibrosis of the skin and other tissues. Effective therapies are lacking. Read More

    Nephrogenic systemic fibrosis.
    Clin Case Rep 2017 Jul 16;5(7):1184-1185. Epub 2017 May 16.
    Division of Nephrology, Hypertension and Renal TransplantationUniversity of FloridaGainesvilleFlorida.
    Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder seen in patients with renal dysfunction, commonly precipitated by administration of gadolinium contrast. There is no consistently successful treatment, but oral steroids, topical dovonex, extracorporeal photopheresis, and plasmapheresis have been tried [http://www.icnfdr. Read More

    effects of different 8-methoxypsoralen treatment protocols for extracorporeal photopheresis on mononuclear cells.
    Cent Eur J Immunol 2017 8;42(1):1-9. Epub 2017 May 8.
    University Medical Center Göttingen, Göttingen, Germany.
    Extracorporeal photopheresis (ECP) is an important second-line therapy for graft-versus-host disease. A central therapeutic mechanism is the induction of immune tolerance through apoptosis in patient's leukocytes, caused by ex vivo incubation with 8-methoxypsoralen (8-MOP) and subsequent UVA irradiation. We hypothesized that different 8-MOP incubation times and an additional 8-MOP removal step could influence the apoptosis kinetics of leukocytes in general and in particular could lead to different apoptotic levels in the leukocyte subpopulations. Read More

    Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
    J Heart Lung Transplant 2017 Sep 29;36(9):921-933. Epub 2017 May 29.
    Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
    Background: Long-term success of lung transplantation is limited by the development of chronic lung allograft dysfunction (CLAD), of which bronchiolitis obliterans syndrome (BOS) is the most common form. This systematic review sought to identify the current evidence base for CLAD-BOS therapies after initial immunosuppressive treatment strategies.

    Methods: The MEDLINE, Embase, and Cochrane Library databases from inception to May 3, 2016, were searched using keywords relating to CLAD-BOS, study designs, and treatments of interest, including extracorporeal photopheresis (ECP), aerosolized cyclosporine, total lymphoid irradiation (TLI), alemtuzumab, and montelukast. Read More

    Lung transplant recipients on long-term extracorporeal photopheresis.
    Clin Transplant 2017 Oct 1;31(10). Epub 2017 Aug 1.
    Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
    Extracorporeal photophoresis (ECP) is an increasingly used therapy to address chronic lung allograft dysfunction (CLAD) following lung transplantation. In 2008, we reported the first single-center experience showing that ECP not only reduces lung function decline in patients with bronchiolitis obliterans syndrome (BOS) but results in stabilization of patients with recurrent acute cellular rejection (ACR). In this study, the original cohort was followed up further 5 years. Read More

    Pediatric Cutaneous Graft Versus Host Disease: A Review.
    Curr Pediatr Rev 2017 ;13(2):100-110
    Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, MA. United States.
    Background: Graft versus host disease (GVHD) is a significant complication following hematopoietic stem cell transplantation in the pediatric population. The most common clinical manifestation of GVHD is in the skin. This article will present a review of key concepts related to pediatric cutaneous GVHD, including pathophysiology, clinical epidemiology, diagnosis, and treatment options. Read More

    The introduction and evaluation of a pressure ulcer risk assessment tool for photopheresis outpatients.
    Br J Nurs 2017 Jun;26(12 Suppl):S16-S22
    Consultant Haematologist, The Rotherham NHS Foundation Trust.
    Chronic graft-versus-host disease (cGVHD) patients are at high risk of compromised skin integrity, and of developing pressure ulcers, which may bleed and/or become infected. The Rotherham Outpatient Screening Tool (ROST) was adapted from the Waterlow score and the Malnutrition Universial Screening Tool (MUST) to suit patients attending an outpatient unit for photopheresis. A review of the screening tool highlighted patients at a higher risk of developing pressure damage during treatment and therefore the unit was able to reduce this risk by the provision of a pressure-relieving cushion (Repose). Read More

    Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease.
    J Clin Apher 2017 Dec 13;32(6):462-473. Epub 2017 Jun 13.
    Photopheresis Unit, Rotherham NHS Trust, Rotherham, South Yorkshire, United Kingdom.
    Extracorporeal Photopheresis (ECP) is a cellular immunotherapy frequently used for steroid-refractory graft-versus-host disease (GVHD). Chronic GVHD (cGVHD), response to ECP is associated with survival benefit. The UVAR-XTSsystem and the more recently developed CELLEXdevice (both Therakos) are the mainstay for ECP-delivery in the UK and US. Read More

    Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study.
    Leuk Lymphoma 2018 Feb 7;59(2):372-380. Epub 2017 Jun 7.
    f Blood Bank Center , Centre Hospitalier Lyon Sud , Pierre Benite , France.
    We performed a prospective multicenter phase 2 study to evaluate the safety and efficacy of prophylactic Extracorporeal Photopheresis (ECP) in adult patients with hematological malignancies early after RIC allo-HSCT on day 21 twice per week during the first two weeks and then once per week for the next four weeks for a total of eight ECP courses. A total of 20 patients were included; 10 were males, median age was 60 years. All patients engrafted, 17 (85%) received the total eight ECP courses. Read More

    Extracorporeal photochemotherapy in mycosis fungoides.
    Transfus Clin Biol 2017 Nov 31;24(4):454-457. Epub 2017 May 31.
    Department of Hematology & BMT Unit, School of Medicine, Ankara University, Cebeci Hospital, 06590 Ankara, Turkey.
    Objectives: Extracorporeal photo-chemotherapy (ECP, photopheresis) is an approved treatment modality for mycosis fungoides (MF). Our aim is to present our ECP data for MF.

    Methods: We retrospectively evaluated 50 MF patients who received ECP for clinical activity, toxicity, and response and outcome rates, and we compared these with combination therapies. Read More

    An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.
    Blood 2017 07 11;130(3):360-367. Epub 2017 May 11.
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA.
    No gold standard has been established as a primary endpoint in trials of initial treatment of chronic graft-versus-host disease (GVHD), and evidence showing the association of any proposed primary endpoint with clinical benefit has not been conclusively demonstrated. To address this gap, we analyzed outcomes in a cohort of 328 patients enrolled in a prospective, multicenter, observational study within 3 months after diagnosis of chronic GVHD. Complete and partial response, stable disease, and progressive disease were defined according to the 2014 National Institutes of Health Consensus Development Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Read More

    Cessation of extracorporeal photopheresis in chronic lung allograft dysfunction: effects on clinical outcome in adults.
    Swiss Med Wkly 2017 05 10;147:w14429. Epub 2017 May 10.
    Division of Pulmonology, University Hospital Zurich, Switzerland.
    Background: Extracorporeal photopheresis (ECP) has been reported to be safe and the ultimate treatment option in lung transplant recipients with chronic lung allograft dysfunction (CLAD), the main overall cause of mortality in lung transplant recipients. However, ECP is not reimbursed in selected health jurisdictions, and reimbursement by health insurance providers is a major issue. In Switzerland, ECP is not recognised by the health authorities as a therapy option for CLAD; thus by the end of 2014, ECP had to be stopped in the majority of adult lung transplant recipients cared for at the University Hospital Zurich because of lack of continuous funding. Read More

    Photopheresis: Advances and Use in Systemic Sclerosis.
    Curr Rheumatol Rep 2017 Jun;19(6):31
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
    Purpose Of Review: Extracorporeal photochemotherapy (photopheresis, ECP) is a cell-based immunomodulatory treatment that separates leukocytes from peripheral blood, exposes them to a photosensitizing agent followed by ultraviolet A light, and then reinfuses them back into the patient. ECP has been found to be effective for graft versus host disease, transplant rejection, and various autoimmune diseases. The mechanism is not well understood but studies have shown clinical benefit in the treatment of systemic sclerosis (SSc). Read More

    Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation.
    Transplant Proc 2017 May;49(4):695-698
    Department of Thoracic Surgery, Policlinico Umberto I, Sapienza University of Rome, Italy.
    Background: Lung transplantation (LT) is only therapeutic option for patients affected by chronic respiratory failure. Chronic rejection, also known as bronchiolitis obliterans syndrome (BOS), is still the main cause of death and the most important factor that influences post-transplantation quality of life. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BOS. Read More

    Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.
    J Clin Apher 2018 Feb 28;33(1):5-13. Epub 2017 Apr 28.
    Hematology department, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, Paris, 75013, France.
    Plerixafor (Mozobil) in combination with granulocyte colony-stimulating factor (G-CSF) has shown to increase mobilization of peripheral blood stem cells (PBSC) as compared to G-CSF alone in patients undergoing autologous stem cell transplantation (ASCT). However, up to 25% of patients treated with G-CSF alone still fail mobilization. Adding plerixafor to poor mobilizers allows to rescue these patients from mobilization failure and to reduce the number of apheresis sessions. Read More

    Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction.
    J Heart Lung Transplant 2018 Mar 24;37(3):340-348. Epub 2017 Mar 24.
    Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address:
    Background: Survival after lung transplantation is limited by chronic lung allograft dysfunction (CLAD). Immunomodulatory therapies such as extracorporeal photopheresis (ECP) and alemtuzumab (AL) have been described for refractory CLAD, but comparative outcomes are not well defined.

    Methods: We retrospectively reviewed spirometric values and clinical outcomes after therapy with ECP, AL, or no treatment (NT) in patients with CLAD who underwent transplant between January 2005 and December 2014. Read More

    A transition from using multi-step procedures to a fully integrated system for performing extracorporeal photopheresis: A comparison of costs and efficiencies.
    J Clin Apher 2017 Dec 17;32(6):474-478. Epub 2017 Apr 17.
    ProcEx Solutions Ltd., Wales, United Kingdom.
    Introduction: The Pitié Salpêtrière Hospital Hemobiotherapy Department, Paris, France, has been providing extracorporeal photopheresis (ECP) since November 2011, and started using the TherakosCELLEXfully integrated system in 2012. This report summarizes our single-center experience of transitioning from the use of multi-step ECP procedures to the fully integrated ECP system, considering the capacity and cost implications.

    Materials And Methods: The total number of ECP procedures performed 2011-2015 was derived from department records. Read More

    Implementation and evaluation of a pre-assessment telephone triage system in an outpatient photopheresis service.
    Br J Nurs 2017 Apr;26(7):400-404
    Consultant Haematologist, The Rotherham NHS Foundation Trust.
    The prompt assessment of patients as fit for photopheresis is imperative to ensure delivery of a safe and efficient service. Before January 2015 the photopheresis unit was reliant on patients contacting the department directly to cancel their appointment if they were unwell or were suffering from any pre-defined exclusion criteria. Methods to reduce the number of cancellations and patients arriving unwell were therefore examined. Read More

    1 OF 23